[go: up one dir, main page]

ZA200703697B - Use of ranolazone in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure - Google Patents

Use of ranolazone in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure

Info

Publication number
ZA200703697B
ZA200703697B ZA200703697A ZA200703697A ZA200703697B ZA 200703697 B ZA200703697 B ZA 200703697B ZA 200703697 A ZA200703697 A ZA 200703697A ZA 200703697 A ZA200703697 A ZA 200703697A ZA 200703697 B ZA200703697 B ZA 200703697B
Authority
ZA
South Africa
Prior art keywords
remodeling
ranolazone
treatment
combination
heart failure
Prior art date
Application number
ZA200703697A
Other languages
English (en)
Inventor
Blackburn Brent
Sabbah Hani
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of ZA200703697B publication Critical patent/ZA200703697B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200703697A 2004-11-09 2007-05-08 Use of ranolazone in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure ZA200703697B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62615404P 2004-11-09 2004-11-09

Publications (1)

Publication Number Publication Date
ZA200703697B true ZA200703697B (en) 2008-09-25

Family

ID=35892429

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200703697A ZA200703697B (en) 2004-11-09 2007-05-08 Use of ranolazone in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure

Country Status (15)

Country Link
US (2) US20060111361A1 (xx)
EP (1) EP1809289A1 (xx)
JP (1) JP2008519770A (xx)
KR (1) KR20070084063A (xx)
CN (1) CN101072562A (xx)
AU (1) AU2005304421A1 (xx)
BR (1) BRPI0517650A (xx)
CA (1) CA2586840A1 (xx)
IL (1) IL183056A0 (xx)
MX (1) MX2007005367A (xx)
NO (1) NO20072934L (xx)
RU (1) RU2007121707A (xx)
SG (1) SG156681A1 (xx)
WO (1) WO2006053161A1 (xx)
ZA (1) ZA200703697B (xx)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040063717A1 (en) * 2002-05-21 2004-04-01 Andrew Wolff Method of treating diabetes
JP5522663B2 (ja) * 2006-09-08 2014-06-18 カーディオポリマーズ， インコーポレイテッド 全体的な心臓のサイズ変更および再形成のための心筋内パターン形成
US20090012413A1 (en) * 2006-09-08 2009-01-08 Sabbah Hani N Cardiac patterning for improving diastolic function
WO2008080012A1 (en) * 2006-12-21 2008-07-03 Cv Therapeutics, Inc. Reduction of cardiovascular symptoms
US20080248112A1 (en) * 2007-02-13 2008-10-09 Brent Blackburn Use of ranolazine for the treatment of coronary microvascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
WO2008101012A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of non-coronary microvascular diseases
JP2010518169A (ja) * 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 心血管疾患の処置のためのラノラジンの使用
US20080233191A1 (en) * 2007-03-22 2008-09-25 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
JP2010523264A (ja) * 2007-04-11 2010-07-15 ヘンリー フォード ヘルス システム 心臓の静脈系を用いた心臓の修復、リサイジング、およびリシェイピング
CN101896181A (zh) * 2007-05-31 2010-11-24 吉利德帕洛阿尔托股份有限公司 用于升高的脑钠肽的雷诺嗪
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
WO2010132696A1 (en) * 2009-05-14 2010-11-18 Gilead Palo Alto, Inc. Ranolazine for the treatment of cns disorders
AU2009202685B1 (en) 2009-06-30 2010-08-19 Ino Therapeutics Llc Methods of treating term and near-term neonates having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension
JP6998942B2 (ja) * 2016-09-19 2022-01-18 アビオメド インコーポレイテッド 心機能を定量化し、心臓の回復を促進する心血管補助システム

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0719558T3 (da) * 1989-06-23 2002-10-07 Syntex Llc Ranolzin og beslægtede piperazin til anvendelse ved behandling af chocktilstande
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US6323226B1 (en) * 1999-10-19 2001-11-27 Texas Heart Institute Treatment of heart disease with cox-2 inhibitors
MXPA02007639A (es) * 2000-02-18 2004-08-23 Cv Therapeutics Inc Inhibidores de la oxidacion parcial de los acidos grasos en el tratamiento de la falla cardiaca congestiva.
US20020052377A1 (en) * 2000-07-21 2002-05-02 Wolff Andrew A. Method for treating angina
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias

Also Published As

Publication number Publication date
NO20072934L (no) 2007-08-08
IL183056A0 (en) 2007-10-31
RU2007121707A (ru) 2008-12-20
EP1809289A1 (en) 2007-07-25
WO2006053161A8 (en) 2006-09-14
MX2007005367A (es) 2007-06-18
AU2005304421A1 (en) 2006-05-18
US20060111361A1 (en) 2006-05-25
SG156681A1 (en) 2009-11-26
US20090176772A1 (en) 2009-07-09
CN101072562A (zh) 2007-11-14
WO2006053161A1 (en) 2006-05-18
KR20070084063A (ko) 2007-08-24
CA2586840A1 (en) 2006-05-18
JP2008519770A (ja) 2008-06-12
BRPI0517650A (pt) 2008-10-14

Similar Documents

Publication Publication Date Title
ZA200703697B (en) Use of ranolazone in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure
GB0700436D0 (en) Impulse therapy for enhanced blood circulation in the body
PL1978947T3 (pl) Nitrooksypochodne do zastosowania w leczeniu dystrofii mięśniowych
EP1814628A4 (en) MEDIUM VOLTAGE THERAPY APPLICATIONS FOR TREATMENT OF HEART DISENESS
PT2083837E (pt) Utilização terapêutica de pelo menos uma neurotoxina botulínica no tratamento da dor induzida por, pelo menos, um agente anti-cancerígeno
PL1912650T3 (pl) Zastosowanie flibanseryny w leczeniu otyłości
IL180929A0 (en) The use of n-aryl diazaspiracyclic compounds in the treatment of addiction
WO2009156182A3 (de) Uracilderivate und deren verwendung
EP1874800A4 (en) DIAGNOSTIC AND THERAPEUTIC AGENTS
EP2214634A4 (en) SKIN MOISTURIZER, PROMOTER OF BLOOD CIRCULATION, AND EXTERNAL SKIN PRODUCTS CONTAINING MOISTURIZER FOR THE SKIN AND THE PROMOTER OF BLOOD CIRCULATION
ZA200709542B (en) Combination therapy in the treatment of cancer
EP1950209A4 (en) TREATMENT AGENT FOR CIRCULATORY INSUFFICIENCY
EP1765832B8 (en) Novel oxabispidine compounds and their use in the treatment of cardiac arrhythmias
EP1952833A4 (en) CLOSED TYPE BLOOD STORAGE TANK AND EXTRACORPORAL BLOOD CIRCULATION SYSTEM USING SAID TANK
GB0415181D0 (en) Compounds for use in the treatment of infection
HK1112394A (en) Use ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure
EP1924326A4 (en) REDUCTION OF MYOKARD DAMAGE AND INCIDENCE OF ARRHYTHMIES FROM LOSS, REDUCTION, OR INTERRUPTION OF CORONARY BLOOD FLOW
PT2182954T (pt) Utilização de ácidos nor-biliares no tratamento de arteriosclerose
GB2411834B (en) Composition for use in the treatment of dry skin conditions
GB0425633D0 (en) Topical formulations for use in the treatment or prevention of dermatological conditions
GB0427637D0 (en) Topical formulations for use in the treatment or prevention of skin cancers
PL1732487T3 (pl) Plaster medyczny do stosowania na skórę
GB2401044B (en) A composition for use in the treatment or prophylaxis of a skin condition in a subject
EP1804795A4 (en) ENANTIOMERIC COMPOSITIONS OF CICLETANINE, ALONE OR COMBINED WITH OTHER AGENTS, USED FOR THERAPEUTIC PURPOSES
WO2007012066A3 (en) TRUNCATED OXIDIZED THYMOSIN β4 AND DERIVATIVES THEREOF